Search Result

Results for "

MEK-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MEK (19) Akt (1) Apoptosis (2) Autophagy (3) c-Met/HGFR (1) Calcium Channel (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) ERK (4) FLT3 (1) Ligands for Target Protein for PROTAC (1) p38 MAPK (1) PDGFR (1) Pim (1) PKC (1) VEGFR (2)
By Research Areas:	Cancer (25) Cardiovascular Disease (2) Inflammation/Immunology (1) Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Targets Recommended: MEK AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib, an antineoplastic agent, is a MEK1/2 inhibitor ^[1].

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 ^[1].

HY-12058

AZD8330 5+ Cited Publications ARRY-424704; ARRY-704	MEK	Cancer
AZD8330 (ARRY-424704) is a potent, uncompetitive *MEK1/MEK2* inhibitor, with an IC₅₀ of 7 nM.

HY-15202

Binimetinib 25+ Cited Publications MEK162; ARRY-162; ARRY-438162	MEK Autophagy	Cancer
Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits MEK with an IC₅₀ of 12 nM.

HY-12042

Pimasertib 5+ Cited Publications AS703026; MSC1936369B	MEK	Cancer
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor ^[1] .

HY-14719

RO4987655 5 Publications Verification CH4987655	MEK	Cancer
RO4987655 is an orally active and highly selective MEK inhibitor with an IC₅₀ of 5.2 nM for inhibition of *MEK1/MEK2*.

HY-U00312

*MEK-IN-1*	MEK	Cancer
MEK-IN-1 is a MEK inhibitor extracted from patent WO2008076415A1.

HY-145701

MEK1/2-IN-2	MEK	Cancer
MEK1/2-IN-2 is a potent ATP-competitive *MEK1/2* inhibitor and shows equipotent inhibition of WT MEK1/2 and a panel of MEK1/2 mutant cell lines ^[1].

HY-12042A

Pimasertib hydrochloride AS703026 hydrochloride; MSC1936369B hydrochloride	MEK	Cancer
Pimasertib hydrochloride is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor ^[1] .

HY-13303

RO 4927350	MEK	Cancer
RO 4927350 is a potent and selective non-ATP-competitive MEK1/2 inhibitor. RO 4927350 exhibits significant antitumor efficacy in a broad spectrum of tumor models ^[1].

HY-126048

JTP-70902	MEK	Cancer
JTP-70902, a p15 ^INK4b-inductive compound, is a *MEK1/2* inhibitor. JTP-70902 exhibits potent antitumor effect ^[1].

HY-50706

Selumetinib Maximum Cited Publications 61 Publications Verification AZD6244; ARRY-142886	MEK Apoptosis	Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation.

HY-15202R

Binimetinib (Standard)	MEK Autophagy	Cancer
Binimetinib (Standard) is the analytical standard of Binimetinib. This product is intended for research and analytical applications. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits MEK with an IC₅₀ of 12 nM.

HY-14691

Refametinib 10+ Cited Publications BAY 869766; RDEA119	MEK	Cancer
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric *MEK1/MEK2* inhibitor with IC₅₀s of 19 nM and 47 nM, respectively.

HY-10254G

Mirdametinib PD0325901; PD325901	MEK	Cancer
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

HY-18086

TCS PIM-1 1 4 Publications Verification SC 204330	Pim	Cancer
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive *Pim-1* kianse inhibitor with an IC₅₀ of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC₅₀s >20000 nM) ^[1].

HY-12062

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive *MEK1/2* inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research ^[1].

HY-113592

ERK-IN-4	ERK	Cancer
ERK-IN-4 is an ERK inhibitor binds preferentially to ERK2 with a K_d of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2 ^[1].

HY-131295

PD0325901-O-C2-dioxolane 2 Publications Verification	MEK Ligands for Target Protein for PROTAC	Cancer
PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader ^[1].

HY-130642

(S,R,S)-AHPC-Me-C10-Br	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-C10-Br is a synthesized E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901 ^[1].

HY-B0023

Azelnidipine 2 Publications Verification CS 905	Calcium Channel MEK	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting *MEK1/2*. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects ^[1] .

HY-13425

Deguelin 5+ Cited Publications (-)-DeguelIN; (-)-cis-DeguelIN	Akt Autophagy Apoptosis	Cancer
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-120485

Raxofelast IRFI-016	p38 MAPK ERK PKC	Cardiovascular Disease
Raxofelast (IRFI-016) is an antioxidant agent in various models of ischemia-reperfusion injury. Raxofelast has antiproliferative activity in H₂O₂-stimulated rat aortic smooth muscle cells. Raxofelast attenuates the activation of mitogen-activating protein kinase (MAPK), ERK kinase 1, 2 (MEK1,2) and protein kinase C (PKC) without affecting Ras expression ^[1].

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[1] .

HY-10338A

Foretinib phosphate	c-Met/HGFR VEGFR	Cancer
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB ^[1].

HY-15196

TAK-285 2 Publications Verification	EGFR	Cancer
TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and *EGFR(HER1)* inhibitor with IC₅₀ of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for *HER1/2* than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity ^[1]. TAK-285 can cross the blood-brain barrier (BBB) .

Cat. No.	Product Name	Type

HY-10254G

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Fluorescent Dye
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

Cat. No.	Product Name	Type

HY-10254G

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Biochemical Assay Reagents
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

Deguelin 5+ Cited Publications (-)-DeguelIN; (-)-cis-DeguelIN	Structural Classification Flavonoids Classification of Application Fields Leguminosae Isoflavanones Source classification Derris trifoliata Lour. Plants Disease Research Fields Biological Pesticide Research Cancer Agricultural Research	Akt Autophagy Apoptosis
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

Hypothemycin	Structural Classification Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[1] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

MEK-IN-1

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Natural
Products